×
About 1,526,140 results

The Greek study in the effects of colchicine in COVID-19 complications prevention (GRECCO-19 study): Rationale and study design
https://www.sciencedirect.com/science/article/pii/S1109966620300610

Colchicine has been utilized safely in a variety of cardiovascular clinical conditions. Among its potential mechanisms of action is the non-selective inhibition of NLRP3 inflammasome which is thought to be a major pathophysiologic component in the clinical course of patients with COVID-19. GRECCO-19 will be a prospective, randomized, open-labeled, controlled study to assess the effects of colch...

The impact of levodopa therapy-induced complications on quality of life in Parkinson’s disease patients in Singapore
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593098/

The objective of this study was to investigate the impact of levodopa therapy-induced complications on the quality of life (QoL) of Parkinson’s disease (PD) patients in Singapore over a 1-year follow-up period. 274 PD patients were prospectively recruited, of which 78 patients completed the follow-up. Patients were evaluated on: (1) motor symptoms, (2) non-motor symptoms, (3) levodopa therapy-i...

Familial hypercholesterolaemia and COVID‐19: triggering of increased sustained cardiovascular risk
https://onlinelibrary.wiley.com/doi/10.1111/joim.13070

Early data from Wuhan, China, show that patients with COVID‐19 are typically male, aged 40 to 60 years, and about one‐third have comorbidities. Moreover, of 138 COVID‐19 patients hospitalized in Wuhan and treated in an intensive care unit (ICU), 25% had cardiovascular disease and 58% hypertension; the respective figures for non‐ICU‐treated COVID‐19 patients were10% and 22% [1]. Based on these e...

Dexamethasone reduces death in hospitalised patients with severe respiratory complications of COVID-19
http://www.ox.ac.uk/news/2020-06-16-dexamethasone-reduces-death-hospitalised-patients-severe-respiratory-complications

In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19, including low-dose dexamethasone (a steroid treatment). Over 11,500 patients have been enrolled from over 175 NHS hospitals in the UK.

Surgical Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586111/

The treatment of motor manifestations of Parkinson's disease (PD) is essentially a trade-off between adequate relief of motor symptoms and prevention and control of motor complications, particularly levodopa-induced dyskinesia (LID). Progression of PD is paralleled by a progressive difficulty in achieving the balance. Functional neurosurgical procedures provide sustained relief of LID in carefu...

Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19
https://www.recoverytrial.net/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19

n March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19, including low-dose dexamethasone (a steroid treatment). Over 11,500 patients have been enrolled from over 175 NHS hospitals in the UK. On 8 June, recruitment to the dexamethasone arm was halted since, in the view of ...

SARS-CoV-2 and Nervous System - Neurological Manifestations in Patients With COVID-19: A Systematic Review
https://www.neurores.org/index.php/neurores/article/view/602/580

Coronavirus (CoV) is a virus infectious disease with a considerable spectrum of clinical presentations. Symptoms ranged from asymptomatic infection to severe pneumonia that may lead to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and several clinical complications. Neurologic symptoms related to CoV have been described recently in the literature. The relationship between SARS-Co...

Fulminant Cerebral Edema as a Lethal Manifestation of COVID-19
https://www.sciencedirect.com/science/article/pii/S1930043320302958

The contribution of neurological symptomatology to morbidity and mortality after infection with Severe Acute Respiratory Syndrome-associated Coronavirus (SARS CoV II), is ill-defined. We hereby present a case of a 57-year old male patient, in excellent physical condition, who was admitted to the Intensive Care Unit (ICU), with respiratory distress duo to SARS CoV II-induced bilateral pneumonia....

A case of COVID-19 pneumonia with cerebral hemorrhage
https://www.thrombosisresearch.com/article/S0049-3848(20)30232-2/fulltext

We agree with Dr. Klok that thromboprophylactic dose low molecular weight heparin should be recommended for all the critically ill patients with 2019 novel coronavirus disease (COVID-19) pneumonia [1]. The very high cumulative incidence of thrombotic complications raises the question if therapeutic anticoagulation should be considered for severe COVID-19 pneumonia patients. As previously report...

Hemorrhagic Stroke in Setting of Severe COVID-19 Infection Requiring Extracorporeal Membrane Oxygenation (ECMO)
https://www.sciencedirect.com/science/article/pii/S1052305720304341

To highlight the increased risk of hemorrhagic stroke secondary to postulated COVID-19 mediated vasculopathy with concomitant ECMO related bleeding complications.

Liver injury in COVID-19: The current evidence
https://journals.sagepub.com/doi/full/10.1177/2050640620924157

Patients with novel coronavirus disease 2019 (COVID-19) experience various degrees of liver function abnormalities. Liver injury requires extensive work-up and continuous surveillance and can be multifactorial and heterogeneous in nature. In the context of COVID-19, clinicians will have to determine whether liver injury is related to an underlying liver disease, drugs used for the treatment of ...

Complications of Shingles
https://www.cdc.gov/shingles/about/complications.html

PHN occurs in the areas where the shingles rash was, even after the rash clears up. It can last for months or years after the rash goes away. The pain from PHN can be so severe and debilitating that it interferes with daily life. About 10 to 18% of people who get shingles will experience PHN. Your risk of PHN increases with age. An older adult with shingles is more likely to develop PHN and ...

Get the New Shingrix Vaccine If You Are 50 or Older
https://www.cdc.gov/shingles/multimedia/shringrix-50-older.html

If you’re 50 or older, get Shingrix Shingrix provides strong protection from shingles and long-term nerve pain. Get Shingrix even if you already had shingles, because you can get the disease more than once. Your risk of shingles and complications increases as you age. You need 2 doses of Shingrix. Get the second dose 2 to 6 months after you get the first dose.

Association of herpes zoster with dementia and effect of antiviral therapy on dementia: a population-based cohort study
https://link.springer.com/article/10.1007/s00406-020-01157-4

We investigated the association between herpes zoster (HZ) and dementia, and the effects of antiviral therapy on the risk of dementia. We used the National Health Insurance Service-National Sample Cohort in South Korea to identify individuals that were followed from January 1, 2002, to December 31, 2013. Occurrences of HZ and dementia were identified using the relevant diagnostic codes. Shing...

Shingles treatment: Does alcohol use affect therapy?
https://www.drugs.com/mcf/shingles-treatment-does-alcohol-use-affect-therapy

Generally, it's best to avoid alcohol during shingles treatment. Shingles (herpes zoster) is a viral infection that causes a painful rash. An episode of shingles usually heals on its own within a few weeks. However, immediate shingles treatment — often including an antiviral drug, such as acyclovir (Zovirax), famciclovir (Famvir) or valacyclovir (Valtrex) — can reduce pain, speed healing and...

What Everyone Should Know about Shingles Vaccine (Shingrix)
https://www.cdc.gov/vaccines/vpd/shingles/public/shingrix/index.html

Shingles vaccination is the only way to protect against shingles and postherpetic neuralgia (PHN), the most common complication from shingles. CDC recommends that healthy adults 50 years and older get two doses of the shingles vaccine called Shingrix (recombinant zoster vaccine), separated by 2 to 6 months, to prevent shingles and the complications from the disease. Your doctor or pharmacist ca...

Epidemiology, treatment and prevention of herpes zoster: A comprehensive review
http://www.ijdvl.com/article.asp?issn=0378-6323;year=2018;volume=84;issue=3;spage=251;epage=262;aulast=Koshy

Herpes zoster is a major health burden that can affect individuals of any age. It is seen more commonly among individuals aged ≥50 years, those with immunocompromised status, and those on immunosuppressant drugs. It is caused by a reactivation of varicella zoster virus infection. Cell-mediated immunity plays a role in this reactivation. Fever, pain, and itch are common symptoms before the onset...

Management of Herpes Zoster (Shingles) and Postherpetic Neuralgia
https://www.aafp.org/afp/2000/0415/p2437.html

Herpes zoster (commonly referred to as “shingles”) and postherpetic neuralgia result from reactivation of the varicella-zoster virus acquired during the primary varicella infection, or chickenpox. Whereas varicella is generally a disease of childhood, herpes zoster and post-herpetic neuralgia become more common with increasing age. Factors that decrease immune function, such as human immunodefi...

The serotonergic system in Parkinson’s patients with dyskinesia: evidence from imaging studies
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060863/

The purpose of review is to review the current status of positron emission tomography (PET) molecular imaging of serotonergic system in Parkinson’s patients who experience levodopa-induced (LIDs) and graft-induced dyskinesias (GIDs). PET imaging studies have shown that Parkinson’s disease is characterized by progressive loss of dopaminergic and serotonergic neurons. Parkinson’s patients who exp...

Out-of-hospital cardiac arrest prognosis during the COVID-19 pandemic
https://link.springer.com/article/10.1007/s11739-020-02428-7

Since the outbreak of coronavirus disease 2019 (COVID-19), many health-care providers have urged patients to limit or delay non-urgent visits to minimize the risk of transmission. Despite these efforts, some health-care services have experienced an ever increasing volume of traffic. As health-care providers are prioritizing emergency and COVID-19 cases, the majority of elective procedures have ...